结直肠癌一线化疗后骨髓抑制的风险预测。

IF 3.3 3区 医学 Q2 ONCOLOGY
Journal of Cancer Pub Date : 2025-01-20 eCollection Date: 2025-01-01 DOI:10.7150/jca.104412
Yanyuan Du, Yuming Liu, Ruiying Fang, Liu Cai, Ying Song, Susu Ma, Huibo Yu, Jin Gao, Hongtai Xiong, Hanyue Zhang, Baihui Li, Honggang Zheng
{"title":"结直肠癌一线化疗后骨髓抑制的风险预测。","authors":"Yanyuan Du, Yuming Liu, Ruiying Fang, Liu Cai, Ying Song, Susu Ma, Huibo Yu, Jin Gao, Hongtai Xiong, Hanyue Zhang, Baihui Li, Honggang Zheng","doi":"10.7150/jca.104412","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with over 1.9 million new cases and 904,000 deaths in 2022. Chemotherapy is a primary treatment for CRC but often leads to myelosuppression, significantly affecting treatment efficacy and patient outcomes. Predictive tools for chemotherapy-induced myelosuppression are currently lacking. <b>Methods:</b> This retrospective study analyzed 855 CRC patients from Guang'anmen Hospital who received first-line chemotherapy (CapeOx, FOLFOX, FOLFIRI) between April 2020 and July 2024. Patients were divided into training (684) and validation (171) groups. Univariate analysis, LASSO regression, and multivariable logistic regression identified risk factors for myelosuppression, and a predictive nomogram was developed and validated using ROC curves, calibration curves, and decision curve analysis. Propensity score matching (PSM) was employed to minimize baseline differences between groups, followed by multivariate logistic regression analysis on the post-PSM data. <b>Results:</b> The incidence of myelosuppression was similar in both groups (33.04% vs. 32.16%). Significant predictors included age, smoking, diabetes, BMI, tumor location, lung metastasis, albumin (ALB) levels, and carcinoembryonic antigen (CEA) levels. The nomogram demonstrated good predictive performance with AUC values of 0.78 and 0.80 for the training and validation groups, respectively, showing consistent and clinically useful predictions. PSM further validated the robustness of the model, confirming BMI as a consistently significant predictor of myelosuppression. <b>Conclusions:</b> The study identified key risk factors for chemotherapy-induced myelosuppression in CRC patients and developed a nomogram for prediction. This tool can help clinicians assess risk and guide treatment decisions. Limitations include potential selection bias and the need for external validation in diverse populations. Future studies should further refine and validate this predictive model.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"16 4","pages":"1379-1396"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786037/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk Prediction of Myelosuppression Following First-line Chemotherapy in Colorectal Cancer.\",\"authors\":\"Yanyuan Du, Yuming Liu, Ruiying Fang, Liu Cai, Ying Song, Susu Ma, Huibo Yu, Jin Gao, Hongtai Xiong, Hanyue Zhang, Baihui Li, Honggang Zheng\",\"doi\":\"10.7150/jca.104412\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with over 1.9 million new cases and 904,000 deaths in 2022. Chemotherapy is a primary treatment for CRC but often leads to myelosuppression, significantly affecting treatment efficacy and patient outcomes. Predictive tools for chemotherapy-induced myelosuppression are currently lacking. <b>Methods:</b> This retrospective study analyzed 855 CRC patients from Guang'anmen Hospital who received first-line chemotherapy (CapeOx, FOLFOX, FOLFIRI) between April 2020 and July 2024. Patients were divided into training (684) and validation (171) groups. Univariate analysis, LASSO regression, and multivariable logistic regression identified risk factors for myelosuppression, and a predictive nomogram was developed and validated using ROC curves, calibration curves, and decision curve analysis. Propensity score matching (PSM) was employed to minimize baseline differences between groups, followed by multivariate logistic regression analysis on the post-PSM data. <b>Results:</b> The incidence of myelosuppression was similar in both groups (33.04% vs. 32.16%). Significant predictors included age, smoking, diabetes, BMI, tumor location, lung metastasis, albumin (ALB) levels, and carcinoembryonic antigen (CEA) levels. The nomogram demonstrated good predictive performance with AUC values of 0.78 and 0.80 for the training and validation groups, respectively, showing consistent and clinically useful predictions. PSM further validated the robustness of the model, confirming BMI as a consistently significant predictor of myelosuppression. <b>Conclusions:</b> The study identified key risk factors for chemotherapy-induced myelosuppression in CRC patients and developed a nomogram for prediction. This tool can help clinicians assess risk and guide treatment decisions. Limitations include potential selection bias and the need for external validation in diverse populations. Future studies should further refine and validate this predictive model.</p>\",\"PeriodicalId\":15183,\"journal\":{\"name\":\"Journal of Cancer\",\"volume\":\"16 4\",\"pages\":\"1379-1396\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786037/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7150/jca.104412\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.104412","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:结直肠癌(CRC)是癌症相关死亡的主要原因,2022年有190多万新病例和90.4万例死亡。化疗是结直肠癌的主要治疗方法,但常导致骨髓抑制,显著影响治疗效果和患者预后。目前缺乏化疗诱导骨髓抑制的预测工具。方法:回顾性分析2020年4月至2024年7月在广安门医院接受一线化疗(CapeOx、FOLFOX、FOLFIRI)的855例结直肠癌患者。患者分为训练组(684)和验证组(171)。单因素分析、LASSO回归和多变量logistic回归确定了骨髓抑制的危险因素,并通过ROC曲线、校准曲线和决策曲线分析建立了预测模态图并进行了验证。采用倾向评分匹配(PSM)来最小化组间基线差异,然后对PSM后的数据进行多变量logistic回归分析。结果:两组患者骨髓抑制发生率相似(33.04% vs. 32.16%)。重要的预测因素包括年龄、吸烟、糖尿病、BMI、肿瘤位置、肺转移、白蛋白(ALB)水平和癌胚抗原(CEA)水平。nomogram显示出良好的预测性能,训练组和验证组的AUC值分别为0.78和0.80,显示出一致性和临床有用的预测。PSM进一步验证了模型的稳健性,证实BMI是骨髓抑制的持续显著预测因子。结论:该研究确定了化疗诱导的结直肠癌患者骨髓抑制的关键危险因素,并制定了用于预测的nomogram。该工具可以帮助临床医生评估风险并指导治疗决策。局限性包括潜在的选择偏差和需要在不同人群中进行外部验证。未来的研究应进一步完善和验证这一预测模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Risk Prediction of Myelosuppression Following First-line Chemotherapy in Colorectal Cancer.

Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with over 1.9 million new cases and 904,000 deaths in 2022. Chemotherapy is a primary treatment for CRC but often leads to myelosuppression, significantly affecting treatment efficacy and patient outcomes. Predictive tools for chemotherapy-induced myelosuppression are currently lacking. Methods: This retrospective study analyzed 855 CRC patients from Guang'anmen Hospital who received first-line chemotherapy (CapeOx, FOLFOX, FOLFIRI) between April 2020 and July 2024. Patients were divided into training (684) and validation (171) groups. Univariate analysis, LASSO regression, and multivariable logistic regression identified risk factors for myelosuppression, and a predictive nomogram was developed and validated using ROC curves, calibration curves, and decision curve analysis. Propensity score matching (PSM) was employed to minimize baseline differences between groups, followed by multivariate logistic regression analysis on the post-PSM data. Results: The incidence of myelosuppression was similar in both groups (33.04% vs. 32.16%). Significant predictors included age, smoking, diabetes, BMI, tumor location, lung metastasis, albumin (ALB) levels, and carcinoembryonic antigen (CEA) levels. The nomogram demonstrated good predictive performance with AUC values of 0.78 and 0.80 for the training and validation groups, respectively, showing consistent and clinically useful predictions. PSM further validated the robustness of the model, confirming BMI as a consistently significant predictor of myelosuppression. Conclusions: The study identified key risk factors for chemotherapy-induced myelosuppression in CRC patients and developed a nomogram for prediction. This tool can help clinicians assess risk and guide treatment decisions. Limitations include potential selection bias and the need for external validation in diverse populations. Future studies should further refine and validate this predictive model.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信